NCT05856513

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ZSP1273

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 68 Years
• Healthy volunteers: Accepted

Summary

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Conditions

• Hepatic Impairment
• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	ZSP1273	Participants receive ZSP1273 orally.
DRUG	ZSP1273	Participants receive ZSP1273 orally.
DRUG	ZSP1273	Participants receive ZSP1273 orally.

Timeline

• Start date: 2023-06-15
• Primary completion: 2023-07-04
• Completion: 2023-07-04
• First posted: 2023-05-12
• Last updated: 2023-12-01

Locations

1 site across 1 country: China